| Literature DB >> 26123122 |
Bin Zhu1, Dan Li1, Yu Ren1, Ying Li1, Yan Wang1, Kai Li1, Buhe Amin1, Ke Gong1, Yiping Lu1, Ming Song2, Nengwei Zhang1.
Abstract
It is undetermined when and how laparoscopic common bile duct exploration (LCBDE) should be used in patients with common bile duct (CBD) stone-related nonsevere acute cholangitis. We aimed to evaluate the effect of LCBDE on the clinical outcome of those patients within (early) or beyond (delayed) 72 hours of emergent admission. Surgery-related complications, length of hospital stay (LOS), and total cost, as well as demographic and clinical parameters were compared between the two groups. Finally, 3 and 5 patients in early and delayed LCBDE group, respectively, had retained stones, which were removed by choledochoscopy before T-tube was removed. Each group had 3 patients who developed biliary leak, which was conservatively cured by the drainage. Shorter LOS and less total cost were observed in early group compared to the late one (13.34 ± 4.48 vs. 18.32 ± 9.13, p < 0.05; 17712 ± 5446.63 vs. 21776 ± 7230.41 ¥RMB, p < 0.05). Improvement of cholangitis was achieved in all patients with LCBDE. None of the patients developed stricture of the CBD after LCBDE. To conclude, both early and delayed LCBDE are safe and effective for the treatment of CBD stone-related nonsevere acute cholangitis during emergent admissions. Early LCBDE may be superior to delayed procedure due to the shorter LOS and less cost.Entities:
Mesh:
Year: 2015 PMID: 26123122 PMCID: PMC4485235 DOI: 10.1038/srep11748
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Comparison of characteristics between early and delayed LCBDE group.
| Age (years), median ± SD | 59.06 ± 15.72 | 59.85 ± 14.6 | 0.841 |
| Sex (Male / Female ) | 15/17 | 20/21 | 0.872 |
| Clinical context and manifestations, n (%) | |||
| History of biliary disease | 19 (59.4) | 22 (53.7) | 0.625 |
| Fever and/or chills | 19 (59.4) | 24 (58.5) | 0.942 |
| Jaundice | 18 (56.3) | 24 (58.5) | 0.845 |
| Abdominal pain (RUQ or upper abdominal) | 31 (96.9) | 39 (95.1) | 0.708 |
| Imaging and/or intra-operative findings | |||
| Diameter of common bile duct (mm) | 11.34 ± 3.19 | 12.93 ± 4.63 | 0.096 |
| No. of solitary CBDS, n (%) | 10 (31.3) | 14 (34.1) | 0.794 |
| No. of multiple CBDS, n (%) | 22 (68.8) | 27 (65.9) | |
| Pathologic type of gallbladder | |||
| Acute cholecystitis, n (%) | 6 (18.8) | 11(26.8) | 0.418 |
| Chronic cholecystitis, n (%) | 26 (81.3) | 30 (73.2) | |
| Duration of surgery (min), median ± SD | 110.78 ± 48.63 | 118.90 ± 59.97 | 0.525 |
| Complications, n (%) | |||
| Pulmonary infection | 1 (3.1) | 0 (0) | 0.438 |
| Retained stone | 3 (9.4) | 5 (12.2) | 0.702 |
| Bile leak | 3 (9.4) | 3 (7.3) | 0.751 |
| 30-day admission, n (%) | 1 (3.1) | 0 (0) | 0.438 |
| LOS (days), median ± SD | 13.34 ± 4.48 | 18.32 ± 9.13 | 0.006 |
| Postoperative hospital stay (days), median ± SD | 11.91 ± 5.78 | 10.33 ± 8.09 | 0.355 |
| Total cost (Yuan in RMB), median ± SD | 17712 ± 5446.63 | 21776 ± 7230.41 | 0.031 |
RUQ, right upper quadrant; CBDS, common bile duct stone; LOS, length of hospital stay.
*P value was obtained from Pearson χ2 test and independent-samples t-test.
Comparison of outcomes in early LCBDE patients before and after surgery.
| Laboratory data (median ± SD) | |||
| WBC count (×109/L) | 11.46 ± 2.93 | 8.84 ± 4.14 | 0.005 |
| ALT (U/L) | 173.84 ± 97.85 | 56.18 ± 39.67 | 0.000 |
| AST (U/L) | 144.96 ± 87.94 | 33.87 ± 20.03 | 0.000 |
| Total bilirubin (μmol/L) | 66.45 ± 40.37 | 27.50 ± 12.55 | 0.000 |
| ALP (U/L) | 178.28 ± 120.23 | 121.75 ± 84.64 | 0.000 |
| γ-GTP (GGT) (U/L) | 366.66 ± 211.26 | 195.72 ± 116.21 | 0.000 |
WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; γ-GTP (GGT), γ-glutamyl transferase (gamma-glutamyl transpeptidase).
*P value was obtained from Paired-samples t-test.
Comparison of outcomes in delayed LCBDE patients before and after surgery.
| Laboratory data (median ± SD) | |||
| WBC count (×109/L) | 10.91 ± 2.63 | 8.54 ± 3.87 | 0.001 |
| ALT (U/L) | 155.17 ± 91.87 | 45.49 ± 29.38 | 0.000 |
| AST (U/L) | 130.68 ± 91.33 | 31.02 ± 15.35 | 0.000 |
| Total bilirubin (μmol/L) | 59.99 ± 41.91 | 31.50 ± 16.61 | 0.000 |
| ALP (U/L) | 206.66 ± 96.13 | 127.15 ± 61.61 | 0.000 |
| γ-GTP (GGT) (U/L) | 435.10 ± 246.89 | 203.90 ± 157.08 | 0.000 |
*P value was obtained from Paired-samples t-test.